Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster medications.

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

(Bloomberg) -- A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly expansion in almost four years. Gross domestic product rose 2 ...

COPENHAGEN, March 2 () - Novo Nordisk said on Monday ‌it will invest 432 million ‌euros ($506.43 million) to expand its ...

FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little/File Photo ...

The Denmark-based drugmaker had already seen its blockbuster weight loss medicine, Wegovy, lose ground to Eli Lilly's (NYSE: ...

Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs ​through U.S. telehealth company Hims & Hers' platform, ending a legal dispute that erupted last month.

March 6 () - Wegovy maker Novo ‌Nordisk plans to ‌sell its weight-loss drugs ​on Hims & Hers Health platform, bringing an end ‌to ⁠a dispute between the two ⁠companies that escalated into a ​legal ...

Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income ...